Home

JAMES R TOBIN

CIK 1190128 · President & CEO · last filed 2026-09-16

JAMES R TOBIN is a President & CEO who has filed 95 SEC Form 4 insider transactions across 9 companies since 2007. The most recent filing, for GMED, was dated Sep 16, 2026. Across all open-market trades the lifetime net is −$23.0M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $38.6M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$38.57M

Companies

9

Total Filings

95

Lifetime Open-Market Net

-$22.99M

Filer Profile

Reported Address
C/O CURIS INC
4 MAGUIRE ROAD
LEXINGTON, MA 02421
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
GMED Director 0 $74.08 $0 -$8.67M 19 2026-09-16
TMDX Director 162,127 $86.42 $14.01M -$14.29M 21 2026-08-17
Lyra Therapeutics, Inc. (LYRA) Delisted Director — $0.70 — $0 4 2025-05-16
Oxford Immunotec Global PLC (OXFD) Delisted Director 4,081 — — $0 7 2020-06-26
Corindus Vascular Robotics, Inc. (CVRS) Delisted Director 106,112 — — $0 9 2019-10-09
CHIASMA, INC (CHMA) Delisted Director — $3.76 — $0 2 2016-06-13
CRIS Director 72 $1.00 $72 -$39.2K 13 2015-01-28
BSX President & CEO 566,550 $43.34 $24.55M $0 4 2009-02-26
APPLIED BIOSYSTEMS INC. (CRA) Delisted Director 0 — — $0 7 2008-06-04

Recent Filings

95 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-09-16 GMED Mixed — -$476.1K EDGAR
2026-09-15 GMED Notice (144) −30,000 -$2.24M EDGAR
2026-08-17 TMDX Gift (G) −18,000 $0 EDGAR
2026-05-22 TMDX Grant (A) +2,922 $0 EDGAR
2026-01-23 GMED Grant (A) — $0 EDGAR
2025-05-23 TMDX Grant (A) +2,134 $0 EDGAR
2025-05-16 Lyra Therapeutics, Inc. (LYRA) Delisted Grant (A) — $0 EDGAR
2025-03-28 GMED Grant (A) — $0 EDGAR
2024-09-17 TMDX Gift (G) — $0 EDGAR
2024-08-09 TMDX Sell (S) −20,000 -$3.19M EDGAR
Showing 1–10 of 95
Page 1 of 10
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.